Are Rare Brain Diseases the Next Commercial Frontier for Gene Therapy?
The biggest trend in gene therapy development is the potential of several treatments for rare neurological diseases to move from the bench to the bedside.
Deborah Phippard
Deborah Phippard, PhD, Chief Scientific Officer at Precision for Medicine, is an industry veteran and expert at biomarker-driven clinical trial design and execution. She is the leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. She spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy.